Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized dose-escalation trial of oxfendazole for loiasis
PACTR202411787280874Phase 2Not yet recruiting
- Sponsor
- Centre de Recherches Médicales de Lambaréné
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of oxfendazole in loiasis (2 arms), sponsored by Centre de Recherches Médicales de Lambaréné. Primary endpoint: Safety and tolerability of oxfendazole. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
oxfendazole
03
Conditions
loiasis
Beyond the preview
Go deeper on PACTR202411787280874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202411787280874.